Randomized trial of short-course high-dose erythropoietin in donation after cardiac death kidney transplant recipients

American Journal of Transplantation

Volumn 12, Issue 7, 2012, Pages 1793-1800

  Aydin, Z ^a   Mallat, M J K ^a   Schaapherder, A F M ^a   Van Zonneveld, A J ^a   Van Kooten, C ^a   Rabelink, T J ^a   De Fijter, Johan W ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Delayed graft function; Donation after cardiac death; Erythropoietin; Kidney transplantation; Randomized trial

Indexed keywords

COTRIMOXAZOLE; CREATININE; CYCLOSPORIN A; DACLIZUMAB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; HEMOGLOBIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RECOMBINANT ERYTHROPOIETIN; STEROID; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONTROLLED STUDY; CONVALESCENCE; CREATININE CLEARANCE; DELAYED GRAFT FUNCTION; DOUBLE BLIND PROCEDURE; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART DEATH; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; KIDNEY VEIN THROMBOSIS; MALE; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM;

ADULT; DEATH; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ERYTHROPOIETIN; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PLACEBOS; TISSUE DONORS;

EID: 84863218218     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04019.x     Document Type: Article

References (24)

1. Keizer KM, de Fijter JW, Haase-Kromwijk BJ, Weimar W. Non-heart-beating donor kidneys in the Netherlands: allocation and outcome of transplantation. Transplantation 2005; 79: 1195-1199. (Pubitemid 40664023)
2. Kokkinos C, Antcliffe D, Nanidis T, Darzi AW, Tekkis P, Papalois V. Outcome of kidney transplantation from nonheart-beating versus heart-beating cadaveric donors. Transplantation 2007; 83: 1193-1199. (Pubitemid 46743680)
3. Doshi MD, Hunsicker LG. Short- and long-term outcomes with the use of kidneys and livers donated after cardiac death. Am J Transplant 2007; 7 122-129. (Pubitemid 44952864)
4. Mehta RL. Timed and targeted therapy for acute kidney injury: a glimpse of the future. Kidney Int 2010; 77: 947-949.
5. Brines M, Cerami A. Discovering erythropoietin's extrahematopoietic functions: biology and clinical promise. Kidney Int 2006; 70: 246-250. (Pubitemid 44086573)
6. Johnson DW, Pat B, Vesey DA, Guan Z, Endre Z, Gobe GC. Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int 2006; 69: 1806-1813. (Pubitemid 43739209)
7. Ehrenreich H, Weissenborn K, Prange H, et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 2009; 40: e647-e656.
8. Najjar SS, Rao SV, Melloni C, et al. Intravenous erythropoietin in patientswith ST-segment elevationmyocardial infarction: REVEAL: A randomized controlled trial. JAMA 2011; 305: 1863-1872.
9. Brines M. The therapeutic potential of erythropoiesis-stimulating agents for tissue protection: A tale of two receptors. Blood Purif 2010; 29: 86-92.
10. Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. MolMed 2002; 8: 495-505. (Pubitemid 36337492)
11. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987; 316: 73-78. (Pubitemid 17052741)
12. Brines M, Grasso G, Fiordaliso F, et al. Erythropoietin mediates tissue protection through an erythropoietin and common betasubunit heteroreceptor. Proc Natl Acad Sci USA 2004; 101: 14907-1412.
13. Boom H, Mallat MJ, de Fijter JW, Zwinderman AH, Paul LC. Delayed graft function influences renal function, but not survival. Kidney Int 2000; 58: 859-866. (Pubitemid 30620036)
14. Martinez F, Kamar N, Pallet N, et al. High dose epoetin beta in the first weeks following renal transplantation and delayed graft function: Results of the Neo-PDGF Study. Am J Transplant 2010; 10: 1695-1700.
15. Hafer C, Becker T, Kielstein JT, et al. High-dose erythropoietin has no effect on short- or long-term graft function following deceased donor kidney transplantation. Kidney Int 2011; 81: 314-320.
16. Jiang S, Chen Y, Zou J, et al. Diverse effects of ischemic pretreatments on the long-term renal damage induced by ischemia-reperfusion. Am J Nephrol 2009; 30: 440-449.
17. Bahlmann FH, Song R, Boehm SM, et al. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 2004; 110: 1006-1012. (Pubitemid 39128626)
18. Beuf dA, D'Haese PC, Verhulst A. Epoetin delta as an antifibrotic agent in the remnant kidney rat: A possible role for transforming growth factor beta and hepatocyte growth factor. Nephron Exp Nephrol 2010; 115: e46-e59.
19. Brines M, Cerami A. Erythropoietin-mediated tissue protection: Reducing collateral damage from the primary injury response. J Intern Med 2008; 264: 405-432.
20. Huang X, Pierce LJ, Chen GL, Chang KT, Spangrude GJ, Prchal JT. Erythropoietin receptor signaling regulates both erythropoiesis and megakaryopoiesis in vivo. Blood Cells Mol Dis 2010; 44: 1-6.
21. Corwin HL, Gettinger A, et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007; 357: 965-976. (Pubitemid 47367076)
22. Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 2010; 363: 1146-1155.
23. Brookhart MA, Schneeweiss S, Avorn J, Bradbury BD, Liu J, Winkelmayer WC. Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA2010; 303: 857-864.
24. Brines M, Patel NS, Villa P, et al. Nonerythropoietic, tissueprotective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci U S A 2008; 105: 10925-10930.